University of Fribourg receives largest ever private donation


Fribourg – Swiss businessman Adolphe Merkle has donated EUR62.5 million to Fribourg University to encourage research and education. The largest-ever private donation to a Swiss university is earmarked for research in the natural sciences, and will be partly used to set up an institute of nanomaterials. The 83-year-old Merkle, who graduated from the university in the 1940s, said he wanted to “give something back to Fribourg”.
The Adolphe Merkle Institute will be attached to the faculty of sciences at the university, and will invest its annual budget of more than EUR3 million in interdisciplinary research into nanomaterials. The institute will allow Fribourg to build on its expertise in nanomaterials, a field which has been researched there since the 1980s. The institute will consist of four research groups led by professors hired for the purpose, and will open early next year. One of the other initiatives to be supported by the foundation is a new chair of innovation management, which will teach students how to bring an idea to commercial fruition.



Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...



London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...



Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...



After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...



The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...



Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...



Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....



Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2015 BIOCOM



All Events


Product of the week


Current issue

All issues